UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC., CELLTRION, INC., and APOTEX, INC.,
Petitioners

v.

REGENERON PHARMACEUTICALS, INC., Patent Owner

Case IPR2021-00881¹ Patent No. 9,254,338 B2

PATENT OWNER'S REPLY ON MOTION TO EXCLUDE EVIDENCE



¹ IPR2022-00258 and IPR2022-00298 have been joined with this proceeding.

TABLE OF CONTENTS

I.	The Board May Strike Petitioner's Improper New Arguments in the Context of a Motion to Exclude
II.	Petitioner's Ground-Expanding Reply Argument Should Be Excluded
III.	Uncited Exhibits and Expert Testimony Should Be Excluded
IV.	Exhibits 1154 and 1173 (Third-Party Complaints) Should be Excluded
V	Appendix A to the Albini Reply Should Be Excluded



TABLE OF AUTHORITIES

Page(s)

Cases

Dexcom Inc. v. Waveform Techs, Inc., IPR2016-01680, Paper 46 (P.T.A.B. Feb. 28, 2018)1
ntel Corp. v. Parkervision, Inc., IPR2020-01265, Paper 44 (P.T.A.B. Jan. 21, 2022)1
ntelligent Bio-Systems, Inc. v. Illumina Cambridge, Ltd., 821 F.3d 1359 (Fed. Cir. 2016)1
aboratoire Francais du Fractionnement et des Biotechnologies SA v. Novo Nordisk Healthcare AG, IPR2017-00028, Paper 109 (P.T.A.B. Apr. 13, 2022)
Reactive Surfaces Ltd., LLP v. Toyota Motor Corp., IPR2017–0057, 2017 WL 5447195 (P.T.A.B. Nov. 9, 2017)4
Catco Prods. Inc. v. Seoul Viosys Co., Ltd., IPR2020-00750, 2021 WL 4822806 (P.T.A.B. Sept. 20, 2021)
Other Authorities
Patent Trial and Appeal Board Consolidated Trial Practice Guide (Nov. 2019)5



I. The Board May Strike Petitioner's Improper New Arguments in the Context of a Motion to Exclude

PO asks the Board to exclude or strike Petitioner's new Reply arguments that expand its asserted Grounds of unpatentability. Paper 83 at 2. As explained in PO's opening brief, there is no procedural barrier to the grant of this request: On multiple occasions, and on analogous facts, the Board has treated party motions to exclude as motions to strike and has excluded arguments that exceed the permitted scope of reply. Id. at 3 (citing Laboratoire Français du Fractionnement et des Biotechnologies SA v. Novo Nordisk Healthcare AG, IPR2017-00028, Paper 109 at 13 (P.T.A.B. Apr. 13, 2022); Intel Corp. v. Parkervision, Inc., IPR2020-01265, Paper 44 at 55-56, 66 n.22, 71-75, 77 (P.T.A.B. Jan. 21, 2022)); see also Dexcom Inc. v. Waveform Techs, Inc., IPR2016-01680, Paper 46 at 30-31 (P.T.A.B. Feb. 28, 2018) ("Federal Circuit case law indicates that a motion to exclude is a proper vehicle for enforcing our rule and trial practice guide regarding the scope of evidence that may be submitted with a reply brief.") (citing, inter alia, Intelligent Bio-Systems, Inc. v. Illumina Cambridge, Ltd., 821 F.3d 1359 (Fed. Cir. 2016)).

Petitioner's assertion that PO failed to provide the requisite notice misses the forest for the trees. PO identified Petitioner's improper, Ground-expanding Reply argument early and often: First in direct correspondence with Petitioner, then in its June 3, 2022, communication with the Board requesting authorization to file a



motion to strike, and again, per the Board's instructions, in its Sur-reply.² *See* Paper 73 at 18. This record does not support Petitioner's suggestion that it was denied timely notice — Petitioner was specifically notified of these issues *before* the due date for PO's evidentiary objections, and duly responded to these arguments in its Opposition. *See Laboratoire Français*, IPR2017-00028, Paper 109 at 12 (striking new reply arguments on PO's motion to exclude where petitioner had the opportunity to respond in opposition). Finally, Petitioner's contention that it was deprived of an opportunity to "correct[] in the form of supplemental evidence" makes no sense. Paper 84 at 2. The filing of supplemental evidence would not cure Petitioner's improper expansion of its Grounds.

II. Petitioner's Ground-Expanding Reply Argument Should Be Excluded

Petitioner's Opposition takes a broad (and incorrect) view of what constitutes "responsive" argument on Reply. In Petitioner's view, if a theory advanced in the Petition is rebutted in the POR, Petitioner may then raise a new theory "in response," which PO can address in sur-reply. Paper 84 at 5-6. But "[s]hifting arguments in



² PO did not file a separate table identifying arguments exceeding the scope of Reply because the Board's June 7 Order provided that such a table should be filed only as an alternative to identifying and addressing such arguments in Sur-Reply, which PO did.

DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

